

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/787,327	04/20/2001	Nathaniel A. Brown	PU3514USW	9628	
23347 7:	590 11/29/2002				
DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY GLAXOSMITHKLINE FIVE MOORE DR., PO BOX 13398			EXAMINER		
			JIANG, SHAOJIA A		
	RESEARCH TRIANGLE PARK, NC 27709-3398			PAPER NUMBER	
			ART UNIT	PAPER NUMBER	
			1617	•	
			DATE MAILED: 11/29/2002	12	

Please find below and/or attached an Office communication concerning this application or proceeding.

а	Application N .	Applicant(s)				
Advisory Action	09/787,327	BROWN ET AL.				
Advisory Action	Examin r	Art Unit				
	Shaojia A. Jiang	1617				
The MAILING DATE of this communication appears n the cover sheet with the correspondence address						
THE REPLY FILED 11 September 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires 6 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
<ul> <li>1. A Notice of Appeal was filed on <u>11 September 2002</u>. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.</li> <li>2. The proposed amendment(s) will not be entered because:</li> </ul>						
(a) they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.  NOTE:						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See attachment.						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: <u>none</u> .						
Claim(s) objected to: none.						
Claim(s) rejected: <u>1-2, 4-10, 12-15, and 22-23 (all)</u> .						
Claim(s) withdrawn from consideration: <u>none</u> .						
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)						
10. Other:						
}						
U.S. Patent and Trademark Office						

Application/Control Number: 09/787,327

Art Unit: 1617

## **Advisory Action**

This Office Action is a response to Applicant's amendment and response <u>after</u>

FINAL filed on September 11, 2002.

5. Applicant's remarks and Berenbaum's reference attached filed September 11, 2002 with respect to the rejection of claims 1-2, 4-10, 12-15, and 22-23 1-10, 12-15, and 22 made under 35 U.S.C. 103(a) as being unpatentable over Korba and Glazier et al. (5,627,165) have been fully considered but are unpersuasive for reasons of record stated in the Final Office Action dated March 12, 2002.

Applicant asserts that the data in Figure 1 of the specification demonstrates synergistic effect for the claimed combination herein by showing that data points falling below the line (the zero interaction line) indicated that the two drugs have synergistic effect. However, Berenbaum's reference is not seen to teach such a similar diagram to Fig. 1 and also not seen to teach data points falling below the line (the zero interaction line) indicated that the two drugs have synergistic effect.

As discussed in the Final Rejection, the evidence presented in specification herein is not seen to support the nonobviousness of the instant claimed invention over the prior art.

Therefore, the claimed invention is clearly obvious in view of the prior art.

Page 2

Application/Control Number: 09/787,327

Art Unit: 1617

Page 3

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (703) 305-1008. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, Ph.D., can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Shaojia A. Jiang, Ph.D. Patent Examiner, AU 1617 November 27, 2002

SRÈENI PADMANABHAN

PRIMARY EXAMINER